IP Library Patent Application 15428095
Patent Application
App. No. 15/428,095

SYSTEM AND METHOD TO MODULATE PAIN AND ITCH THROUGH CUTANEOUS TRANSFER OF GENETIC INFORMATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/428,095
Abstract

One embodiment is directed to a system for altering the function of a sensory unit that innervates a targeted tissue region in an animal, the sensory unit being configured to express a light-responsive protein, comprising a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure; and a light source configured to provide light to the light delivery element; wherein the targeted tissue structure is illuminated transcutaneously with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light-responsive protein to the radiation.

Claims (18)

1 . A system for altering the function of a sensory unit that innervates a targeted tissue region in an animal, the sensory unit being configured to express a light-responsive protein, comprising:

a. a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure; and

b. a light source configured to provide light to the light delivery element;

wherein the targeted tissue structure is illuminated transcutaneously with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light-responsive protein to the radiation.

2 . The system of claim 1 , wherein the light source is selected from the group consisting of a laser, a light emitting diode, and a chemiluminescent compound.

3 . The system of claim 1 , wherein the sensory unit is adjacent a stratum corneum layer that has been altered prior to administration of one or more clinical compounds configured to cause the sensory unit to express the light-responsive protein.

4 . The system of claim 3 , wherein the stratum corneum layer has been altered using a configuration selected from the group consisting of: a tape stripping configuration, a dermabrasion configuration, a microdermabrasion configuration, a depilatory compound application configuration, a sonophoresis configuration, an iontophoresis configuration, an electroporation configuration, a microdermabrasion configuration, a microneedle configuration, a laser ablation configuration, and an optoporation configuration.

5 . The system of claim 1 , wherein the light-responsive protein is a stimulatory opsin.

6 . The system of claim 5 , wherein the stimulatory opsin is selected from the group consisting of ChR2, C1V1-T, C1V1-TT, CatCh, VChR1-SFO, and ChR2-SFO.

7 . The system of claim 1 , wherein the light-responsive protein is an inhibitory opsin.

8 . The system of claim 7 , wherein the inhibitory opsin is selected from the group consisting of NpHR, eNpHR 1.0, eNpHR 2.0, eNpHR 3.0, Mac, Mac 3.0, Arch, ArchT, iChR, iC1C2, iC++, SwiChR++, and JAWS.

9 . The system of claim 1 , wherein the sensory unit is configured to express the light-responsive protein via administration into the targeted tissue region of an adeno-associated virus wherein a viral genome encodes at least one light responsive protein which becomes expressed in the sensory unit.

10 . The system of claim 9 , wherein the adeno associated virus has a coat protein selected from the group consisting of adeno-associated virus strain 1, adeno-associated virus strain 6, and adeno-associated virus strain 8.

11 . The system of claim 1 , wherein the targeted tissue region is selected based at least in part upon an undesired sensory response selected from the group consisting of acute pain, chronic pain, allodynia, ectopic pain, neuropathic pain, itch, and parathesia.

12 . The system of claim 1 , wherein the targeted tissue region is selected based at least in part upon anesthesia.

13 . The system of claim 1 , wherein the targeted tissue region is selected based at least in part upon a feeling of satiation.

14 . The system of claim 9 , wherein the adeno-associated virus is self-complementary.

15 . The system of claim 2 , wherein the light source is a chemiluminescent compound created using a chemiluminescent reaction that is based at least in part upon a peroxyoxalate oxidation reaction.

Assignments (2)
SECURITY INTEREST Recorded Nov 3, 2020
From: CIRCUIT THERAPEUTICS, INC.
To: MAGICHEART INVESTMENTS, LLC
Reel/Frame 054291/0504 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2017
From: TOWNE, CHRISTOPHER L.; ANDERSEN, DAN
To: CIRCUIT THERAPEUTICS, INC.
Reel/Frame 043058/0680 →